Senti Bio Q3 net loss $18.1M; cash $12.2M; ASH data ahead

Senti Biosciences, Inc.

2025-Q3 EPS reported -$2.25 vs consensus -$0.58 ▼ miss (-289.3%)

Cash and cash equivalents $12.2M as of Sep 30, 2025, down from $48.3M at Dec 31, 2024.
Net loss $18.1M ($0.69 per share) for Q3 2025; R&D expense $10.5M, G&A $6.4M.
Phase 1 SENTI-202 in AML: updated clinical data to be presented at ASH meeting Dec 6-9, 2025.
Abstracts accepted for oral and poster presentations at ASH; company will host webcast.
No revenue; pre-commercial biotech focused on gene circuit platform for cell therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.